Palkion Selects Novel Oral Development Candidate for the Treatment of AnemiaMonday, June 29, 2009 @ 5:00AMPalkion, Inc. announced today that it has initiated preclinical development studies for its orally available anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl Hydroxylase enzyme system.